CA-125: A potential prognostic indicator in patients with cervical cancer?

Gary L. Goldberg, Avi Sklar, Katherine A. O'Hanlan, Phyllis A. Levine, Carolyn D. Runowicz

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We evaluated 104 patients with newly diagnosed carcinoma of the cervix. Pre- and post-therapy and followup CA-125 levels were measured in 64 patients. Fifty-five patients (86%) had squamous cell carcinoma and 9 (14%) had adenocarcinoma of the cervix. At initial presentation 19 (30%) had CA-125 levels >35 U/ml, 12 (19%) had levels of 16-35 U/ml, and 33 (51%) had levels <16 U/ml. Of the 11 patients who had pre- and post-treatment levels >35 U/ml, 10 are dead of the disease and 1 is alive with persistent or recurrent disease. Of the 20 patients with elevated CA-125 levels at presentation who reverted to normal after therapy, 19 are clinically without evidence of disease at 14-46 months (median 27 months). Of the 33 patients with normal pre- and post-therapy CA-125 levels, 31 are clinically without evidence of disease. Two of these thirty-three patients had increasing CA-125 levels during routine follow-up and both have disease recurrence confirmed. There was no apparent correlation between CA-125 level and tumor type, tumor grade, or stage of disease. Our data suggest that patients with initially elevated CA-125 levels that revert to normal after therapy have a favorable prognosis. Persistent elevation of CA-125 levels during and after therapy in patients with carcinoma of the cervix was associated with a poor prognosis.

Original languageEnglish (US)
Pages (from-to)222-224
Number of pages3
JournalGynecologic Oncology
Volume40
Issue number3
DOIs
StatePublished - 1990

Fingerprint

Uterine Cervical Neoplasms
Cervix Uteri
Therapeutics
Carcinoma
Squamous Cell Carcinoma
Neoplasms
Adenocarcinoma
Recurrence

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Goldberg, G. L., Sklar, A., O'Hanlan, K. A., Levine, P. A., & Runowicz, C. D. (1990). CA-125: A potential prognostic indicator in patients with cervical cancer? Gynecologic Oncology, 40(3), 222-224. https://doi.org/10.1016/0090-8258(90)90281-O

CA-125 : A potential prognostic indicator in patients with cervical cancer? / Goldberg, Gary L.; Sklar, Avi; O'Hanlan, Katherine A.; Levine, Phyllis A.; Runowicz, Carolyn D.

In: Gynecologic Oncology, Vol. 40, No. 3, 1990, p. 222-224.

Research output: Contribution to journalArticle

Goldberg, GL, Sklar, A, O'Hanlan, KA, Levine, PA & Runowicz, CD 1990, 'CA-125: A potential prognostic indicator in patients with cervical cancer?', Gynecologic Oncology, vol. 40, no. 3, pp. 222-224. https://doi.org/10.1016/0090-8258(90)90281-O
Goldberg, Gary L. ; Sklar, Avi ; O'Hanlan, Katherine A. ; Levine, Phyllis A. ; Runowicz, Carolyn D. / CA-125 : A potential prognostic indicator in patients with cervical cancer?. In: Gynecologic Oncology. 1990 ; Vol. 40, No. 3. pp. 222-224.
@article{6e3c656bd81e41e99fff1f2f53de6366,
title = "CA-125: A potential prognostic indicator in patients with cervical cancer?",
abstract = "We evaluated 104 patients with newly diagnosed carcinoma of the cervix. Pre- and post-therapy and followup CA-125 levels were measured in 64 patients. Fifty-five patients (86{\%}) had squamous cell carcinoma and 9 (14{\%}) had adenocarcinoma of the cervix. At initial presentation 19 (30{\%}) had CA-125 levels >35 U/ml, 12 (19{\%}) had levels of 16-35 U/ml, and 33 (51{\%}) had levels <16 U/ml. Of the 11 patients who had pre- and post-treatment levels >35 U/ml, 10 are dead of the disease and 1 is alive with persistent or recurrent disease. Of the 20 patients with elevated CA-125 levels at presentation who reverted to normal after therapy, 19 are clinically without evidence of disease at 14-46 months (median 27 months). Of the 33 patients with normal pre- and post-therapy CA-125 levels, 31 are clinically without evidence of disease. Two of these thirty-three patients had increasing CA-125 levels during routine follow-up and both have disease recurrence confirmed. There was no apparent correlation between CA-125 level and tumor type, tumor grade, or stage of disease. Our data suggest that patients with initially elevated CA-125 levels that revert to normal after therapy have a favorable prognosis. Persistent elevation of CA-125 levels during and after therapy in patients with carcinoma of the cervix was associated with a poor prognosis.",
author = "Goldberg, {Gary L.} and Avi Sklar and O'Hanlan, {Katherine A.} and Levine, {Phyllis A.} and Runowicz, {Carolyn D.}",
year = "1990",
doi = "10.1016/0090-8258(90)90281-O",
language = "English (US)",
volume = "40",
pages = "222--224",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - CA-125

T2 - A potential prognostic indicator in patients with cervical cancer?

AU - Goldberg, Gary L.

AU - Sklar, Avi

AU - O'Hanlan, Katherine A.

AU - Levine, Phyllis A.

AU - Runowicz, Carolyn D.

PY - 1990

Y1 - 1990

N2 - We evaluated 104 patients with newly diagnosed carcinoma of the cervix. Pre- and post-therapy and followup CA-125 levels were measured in 64 patients. Fifty-five patients (86%) had squamous cell carcinoma and 9 (14%) had adenocarcinoma of the cervix. At initial presentation 19 (30%) had CA-125 levels >35 U/ml, 12 (19%) had levels of 16-35 U/ml, and 33 (51%) had levels <16 U/ml. Of the 11 patients who had pre- and post-treatment levels >35 U/ml, 10 are dead of the disease and 1 is alive with persistent or recurrent disease. Of the 20 patients with elevated CA-125 levels at presentation who reverted to normal after therapy, 19 are clinically without evidence of disease at 14-46 months (median 27 months). Of the 33 patients with normal pre- and post-therapy CA-125 levels, 31 are clinically without evidence of disease. Two of these thirty-three patients had increasing CA-125 levels during routine follow-up and both have disease recurrence confirmed. There was no apparent correlation between CA-125 level and tumor type, tumor grade, or stage of disease. Our data suggest that patients with initially elevated CA-125 levels that revert to normal after therapy have a favorable prognosis. Persistent elevation of CA-125 levels during and after therapy in patients with carcinoma of the cervix was associated with a poor prognosis.

AB - We evaluated 104 patients with newly diagnosed carcinoma of the cervix. Pre- and post-therapy and followup CA-125 levels were measured in 64 patients. Fifty-five patients (86%) had squamous cell carcinoma and 9 (14%) had adenocarcinoma of the cervix. At initial presentation 19 (30%) had CA-125 levels >35 U/ml, 12 (19%) had levels of 16-35 U/ml, and 33 (51%) had levels <16 U/ml. Of the 11 patients who had pre- and post-treatment levels >35 U/ml, 10 are dead of the disease and 1 is alive with persistent or recurrent disease. Of the 20 patients with elevated CA-125 levels at presentation who reverted to normal after therapy, 19 are clinically without evidence of disease at 14-46 months (median 27 months). Of the 33 patients with normal pre- and post-therapy CA-125 levels, 31 are clinically without evidence of disease. Two of these thirty-three patients had increasing CA-125 levels during routine follow-up and both have disease recurrence confirmed. There was no apparent correlation between CA-125 level and tumor type, tumor grade, or stage of disease. Our data suggest that patients with initially elevated CA-125 levels that revert to normal after therapy have a favorable prognosis. Persistent elevation of CA-125 levels during and after therapy in patients with carcinoma of the cervix was associated with a poor prognosis.

UR - http://www.scopus.com/inward/record.url?scp=0025911183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025911183&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(90)90281-O

DO - 10.1016/0090-8258(90)90281-O

M3 - Article

C2 - 2013443

AN - SCOPUS:0025911183

VL - 40

SP - 222

EP - 224

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -